Prediction of adjuvant chemotherapy response in triple negative breast cancer with discovery and targeted proteomics

BACKGROUND: Triple-negative breast cancer (TNBC) accounts for 15–20% of all breast cancers and usually requires the administration of adjuvant chemotherapy after surgery but even with this treatment many patients still suffer from a relapse. The main objective of this study was to identify proteomic...

Descripción completa

Detalles Bibliográficos
Autores principales: Gámez-Pozo, Angelo, Trilla-Fuertes, Lucía, Prado-Vázquez, Guillermo, Chiva, Cristina, López-Vacas, Rocío, Nanni, Paolo, Berges-Soria, Julia, Grossmann, Jonas, Díaz-Almirón, Mariana, Ciruelos, Eva, Sabidó, Eduard, Espinosa, Enrique, Fresno Vara, Juan Ángel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464546/
https://www.ncbi.nlm.nih.gov/pubmed/28594844
http://dx.doi.org/10.1371/journal.pone.0178296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464546/
https://www.ncbi.nlm.nih.gov/pubmed/28594844
http://dx.doi.org/10.1371/journal.pone.0178296

Ejemplares similares